Bispecific antibodies and their applications

Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Gaowei, Wang, Zujian, Hao, Mingju, Li, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687327/
https://www.ncbi.nlm.nih.gov/pubmed/26692321
http://dx.doi.org/10.1186/s13045-015-0227-0
_version_ 1782406613365161984
author Fan, Gaowei
Wang, Zujian
Hao, Mingju
Li, Jinming
author_facet Fan, Gaowei
Wang, Zujian
Hao, Mingju
Li, Jinming
author_sort Fan, Gaowei
collection PubMed
description Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites. The approval of catumaxomab (anti-EpCAM and anti-CD3) and blinatumomab (anti-CD19 and anti-CD3) has become a major milestone in the development of bsAbs. Currently, more than 60 different bsAb formats exist, some of them making their way into the clinical pipeline. This review summarizes diverse formats of bsAbs and their clinical applications and sheds light on strategies to optimize the design of bsAbs.
format Online
Article
Text
id pubmed-4687327
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46873272015-12-23 Bispecific antibodies and their applications Fan, Gaowei Wang, Zujian Hao, Mingju Li, Jinming J Hematol Oncol Review Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites. The approval of catumaxomab (anti-EpCAM and anti-CD3) and blinatumomab (anti-CD19 and anti-CD3) has become a major milestone in the development of bsAbs. Currently, more than 60 different bsAb formats exist, some of them making their way into the clinical pipeline. This review summarizes diverse formats of bsAbs and their clinical applications and sheds light on strategies to optimize the design of bsAbs. BioMed Central 2015-12-21 /pmc/articles/PMC4687327/ /pubmed/26692321 http://dx.doi.org/10.1186/s13045-015-0227-0 Text en © Fan et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Fan, Gaowei
Wang, Zujian
Hao, Mingju
Li, Jinming
Bispecific antibodies and their applications
title Bispecific antibodies and their applications
title_full Bispecific antibodies and their applications
title_fullStr Bispecific antibodies and their applications
title_full_unstemmed Bispecific antibodies and their applications
title_short Bispecific antibodies and their applications
title_sort bispecific antibodies and their applications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687327/
https://www.ncbi.nlm.nih.gov/pubmed/26692321
http://dx.doi.org/10.1186/s13045-015-0227-0
work_keys_str_mv AT fangaowei bispecificantibodiesandtheirapplications
AT wangzujian bispecificantibodiesandtheirapplications
AT haomingju bispecificantibodiesandtheirapplications
AT lijinming bispecificantibodiesandtheirapplications

Ejemplares similares